SOPHiA GENETICS SA

NASDAQ•SOPH

CEO: Dr. Jurgi Camblong M.B.A., Ph.D.

Sector: Healthcare

Industry: Medical - Healthcare Information Services

Listing Date: 2021-07-23

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Contact Information

La PiEce 12, Rolle, 1180, Switzerland

41-21-694-10-60

www.sophiagenetics.com

Market Cap

$304.63M

P/E (TTM)

-3.9

40.8

Dividend Yield

52W High

$5.70

52W Low

$2.58

52W Range

61%

Rank63Top 94.0%

1.8

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 1.8 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$21.71M+0.00%

4-Quarter Trend

EPS

-$0.28+0.00%

4-Quarter Trend

FCF

-$9.28M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Strong Revenue Growth Revenue 77.3M USD, up 19% from 65.2M USD in 2024, driven by increased platform usage and strong volume growth in key regions.

Customer Base Expansion Core Genomics Customers reached 528, up from 472 in 2024, reflecting continued acquisition momentum and successful land-and-expand commercial model across global markets.

Platform Usage Increase Platform analysis volume reached 391.7K, up 11% from 352.6K in 2024, driven by strong growth in Hematological Oncology applications and regional expansion.

Net Dollar Retention Improvement Net dollar retention increased to 115% from 104% in 2024, demonstrating strong growth across existing customer base and higher average product selling prices.

Risk Factors

Persistent Net Losses Net loss 79.0M USD in 2025, up from 62.5M USD in 2024, with accumulated deficit reaching 519.3M USD, impacting overall financial stability and profitability.

Litigation Legal Expenses Guardant Health patent infringement claims resulted in 2.4M USD legal expenses in 2H 2025, potentially blocking future development and commercialization efforts in key markets.

Regulatory Approval Uncertainty Inability to obtain or maintain regulatory clearances for IVD applications could limit commercial potential and negatively impact future revenue growth and market expansion.

Debt Covenant Risks 50.0M USD debt under Perceptive Credit Agreement requires maintaining qualified cash and revenue covenants, limiting financial flexibility and operational planning for future growth.

Outlook

Continued R&D Investment Plan to devote substantial resources to expand SOPHiA DDM Platform features, applications, and data modalities to drive future revenue growth and market adoption.

Global Market Expansion Focus on penetrating U.S. market and under-penetrated regions in APAC and EMEA through direct sales force and strategic industry collaborations to drive growth.

Strategic Capital Allocation Utilize existing cash and potential additional financing to fund operations, research, and development while managing debt and capital requirements for future business needs.

Regulatory Strategy Focus Intend to pursue IVD status and FDA approval for specific solutions to expand market reach and drive long-term profitability in the clinical market.

Peer Comparison

Revenue (TTM)

AGL

$5.93B

-2.1%

TBRG

$349.88M

+3.1%

$241.52M

-4.2%

Gross Margin (Latest Quarter)

ACIU

100.0%

+0.0pp

CLLS

93.3%

+10.5pp

68.1%

+6.7pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
LRMR	$480.16M	-3.3	-91.8%	2.3%
CLLS	$383.17M	-11.4	-31.8%	27.0%
NRC	$368.64M	30.6	58.5%	58.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

6.9%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 4, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data